CoChat

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

O'Shaughnessy, Joyce, Osborne, Cynthia, Pippen, John E., Yoffe, Mark, Patt, Debra, Rocha, Christine, Koo, Ingrid Chou, Sherman, Barry M., Bradley, Charles · 2011 · New England Journal of Medicine

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa1011418

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 876

Metadata

Authors
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
Affiliations
Texas Oncology (US)
Venue
New England Journal of Medicine
Published
2011-01-20
Volume
364
Issue
3
Pages
205-214
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2111429259
Cited by
817
References
32
Citations by year
2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
FWCI
70.91
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
MeSH terms
Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. https://app.cochat.ai/papers/10.1056/nejmoa1011418
The paper
O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011). Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1011418

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.